Article
Clinical Neurology
Johanna Balslev Andersen, Finn Sellebjerg, Melinda Magyari
Summary: This study found no increased association of adverse pregnancy outcomes in newborns with fetal exposure to disease-modifying drugs (DMDs) when compared with either DMD-unexposed pregnancies or the general population.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Stephen L. Hauser, Anne H. Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G. Meuth, Paul S. Giacomini, Francesco Sacca, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A. Haring, Valentine Jehl, Bernd C. Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi, Ludwig Kappos
Summary: Ofatumumab demonstrates good safety and tolerability in the treatment of RMS patients for up to 3.5 years, with no new safety risks identified, supporting its established effectiveness.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Bernardita Soler, Ethel Ciampi, Reinaldo Uribe-San-Martin, Karina Keller, Macarena Astudillo, Valeria Charaf, Ana Reyes, Elizabeth Vergara, Claudia Carcamo
Summary: This study investigated pregnancy decision-making and outcomes in women with multiple sclerosis (MS) before and after diagnosis. The results showed that after MS diagnosis, women tend to have fewer children at an older age, with a higher rate of cesarean sections. However, there were no significant differences in newborn outcomes between the two groups.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Article
Clinical Neurology
Johanna Balslev Andersen, Malthe Faurschou Wandall-Holm, Melinda Magyari
Summary: The study investigated the association of adverse perinatal outcomes in newborns with maternal or paternal exposure to teriflunomide, and found no increased prevalence of spontaneous abortion, preterm birth, congenital malformations, low Apgar score, or being small for gestational age in newborns with exposure to teriflunomide compared to the general population.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Clinical Neurology
Sigal Kaplan, Mikhail Zeygarnik, Tal Stern, Kerstin Hellwig
Summary: This study assessed the impact of in utero exposure to glatiramer acetate (GA) on pregnancy and fetal outcomes. The results showed that exposure to 20 and 40 mg/mL GA in all three trimesters of pregnancy does not appear to be related to adverse pregnancy or infant outcomes.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Immunology
Simon Faissner, Neele Heitmann, Carlos Plaza-Sirvent, Paulina Trendelenburg, Ulas Ceylan, Jeremias Motte, Clara Bessen, Doris Urlaub, Carsten Watzl, Oliver Overheu, Anke Reinacher-Schick, Kerstin Hellwig, Stephanie Pfaender, Ingo Schmitz, Ralf Gold
Summary: This study investigated the immune cell alterations and immune response in patients receiving early ofatumumab treatment and compared them to healthy controls following SARS-CoV-2 vaccination. The results showed that ofatumumab treatment led to depletion of B cells and changes in certain T cell subpopulations. The humoral immune response to SARS-CoV-2 was impaired, while the cellular immune response was preserved.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Clinical Neurology
Helene Tillaut, Adeline Degremont, Sandrine Kerbrat, Jonathan Roux, Emmanuelle Le Page, Christelle Mainguy, Solene Duros, Elisabeth Polard, Emmanuelle Leray
Summary: The pregnancy incidence rate for women with multiple sclerosis was approximately 4.5 per 100 person-years. The probability of having a pregnancy exposed to disease-modifying therapies increased over time, with those who stopped treatment within the previous year having the highest probability of live birth.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Anne H. Cross, Silvia Delgado, Mario Habek, Maria Davydovskaya, Brian J. Ward, Bruce A. C. Cree, Natalia Totolyan, Ratnakar Pingili, Linda Mancione, Xixi Hu, Roseanne Sullivan, Wendy Su, Ronald Zielman, Ayan Das Gupta, Xavier Montalban, Kevin Winthrop
Summary: The study analyzed COVID-19 cases in ofatumumab-treated RMS patients from December 2019 to September 2021. Most cases were mild or moderate in severity, with 9% classified as severe/life-threatening. Out of 245 patients, 2 died from COVID-19, and breakthrough infections were uncommon among vaccinated patients.
NEUROLOGY AND THERAPY
(2022)
Article
Pharmacology & Pharmacy
Itai Gueta, Adi Braun, Adi Gilan, Maya Berlin, Elkana Kohn, Dana Barchel, Noa Markovits, Matitiahu Berkovitch, Ronen Loebstein
Summary: Short-term gestational exposure to papaverine adjusted for indication was not associated with preterm deliveries, CS, lower birthweight, small for gestational age or perinatal death. Rate of major malformations among 46 first trimester exposures was comparable to controls.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Clinical Neurology
Amit Bar-Or, Rany Aburashed, Angel R. Chinea, Barry A. Hendin, Elisabeth Lucassen, Xiangyi Meng, James Stankiewicz, Mark J. Tullman, Anne H. Cross
Summary: This study assessed the humoral immune response to COVID-19 vaccination in patients with relapsing multiple sclerosis (RMS) treated with ofatumumab. The results showed that patients who received 3 vaccine doses had a better humoral immune response. Younger patients without anti-CD20 therapy had better response to the vaccine.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Public, Environmental & Occupational Health
Sigal Kaplan, Mikhail Zeygarnik, Tal Stern
Summary: Published data support the safety of glatiramer acetate in pregnant or breastfeeding multiple sclerosis patients, with limited long-term data. This study aimed to assess pregnancy, fetal, and infant outcomes following maternal exposure to glatiramer acetate. The results suggest that maternal exposure to glatiramer acetate does not appear to be associated with adverse pregnancy, fetal, or infant outcomes, supporting the safety of both 20-mg/mL and 40-mg/mL glatiramer acetate treatments during pregnancy and breastfeeding.
Review
Pharmacology & Pharmacy
Baris Karadas, Nusret Uysal, Hilal Erol, Selin Acar, Meltem Koc, Tijen Kaya-Temiz, Gideon Koren, Yusuf C. Kaplan
Summary: This meta-analysis aimed to investigate the association between maternal exposure to statins and the risk of major congenital malformations and other adverse pregnancy outcomes. The results showed no significant increase in the rate of major congenital malformations in the statin-exposed group compared to the control group, but a higher risk of heart defects was detected. Additionally, the statin-exposed group had a lower live birth rate and a higher spontaneous abortion rate.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Immunology
Julia Baguna Torres, Jay Roodselaar, Megan Sealey, Marina Ziehn, Marc Bigaud, Rainer Kneuer, David Leppert, Gisbert Weckbecker, Bart Cornelissen, Daniel C. Anthony
Summary: This study investigated the distribution and efficacy of ofatumumab and ocrelizumab in huCD20 transgenic mice, revealing differences in tissue distribution patterns between subcutaneous and intravenous administration, with the possibility of more direct access to lymph nodes through the lymphatic system with subcutaneous administration. Additionally, preliminary findings suggest that ofatumumab may be more effective than ocrelizumab at controlling MS-like pathology in the brain.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Tjalf Ziemssen, Marie Groth, Benjamin Ettle, Tobias Bopp
Summary: This study investigated the immune response in multiple sclerosis (MS) patients receiving ofatumumab after SARS-CoV-2 mRNA vaccination. The results showed that these patients were able to mount a T-cell response and increase levels of neutralizing antibodies, although it was slightly less pronounced compared to the control group.
Article
Clinical Neurology
Russo Cinzia Valeria, Lanzillo Roberta, Sacca Francesco, Moccia Marcello, Carotenuto Antonio, Brescia Morra Vincenzo
Summary: Data on pregnancy outcomes in women treated with alemtuzumab are limited, but real-world cases show that the risk of pregnancy post-treatment still exists, necessitating a focus on pregnancy prevention measures. Continued monitoring and vigilance for potential complications are important during treatment.
NEUROLOGICAL SCIENCES
(2021)
Article
Clinical Neurology
Zahra Ghadimi Korka, Shohreh Noorizadeh Dehkordi, Soheil Mansour Sohani, Marzieh Yassin
Summary: The Trunk Impairment Scale (TIS) in Persian has been found to be a relevant and reliable tool for assessing trunk abnormalities in Persian-speaking people with multiple sclerosis (PWMS).
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2024)
Letter
Clinical Neurology
Daniele Caliendo, Maria Carmela Grassia, Antonio Carotenuto, Maria Petracca, Roberta Lanzillo, Vincenzo Brescia Morra, Marcello Moccia
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2024)
Article
Clinical Neurology
Maddalena Sparaco, Elisabetta Maida, Floriana Bile, Renato Vele, Luigi Lavorgna, Giuseppina Miele, Simona Bonavita
Summary: The SDQ was translated into Italian and validated for use in pwMS to detect swallowing disturbances. The 14-item SDQ demonstrated high internal consistency, good accuracy, and reliability in pwMS, making it a readily applicable tool for investigating dysphagia in MS.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2024)
Article
Clinical Neurology
Leticia Rodrigues Gomes, Benito Pereira Damasceno, Brunno Machado de Campos, Alfredo Damasceno
Summary: This study found that patients with multiple sclerosis (MS) have more frequent work restrictions and impairment in money management and driving abilities compared to controls. Cognitive function, physical disability, and MS lesion burden are strongly associated with work restrictions, and social cognition can influence financial capacity. Cognitive and brain reserve can help retain some of these daily occupations.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2024)
Letter
Clinical Neurology
Kaitlin E. Riegler, John Beauvais, Lindsay O. Neto, Elizabeth S. Gromisch
Summary: This study examined the differences in resilience levels among individuals with multiple sclerosis (PwMS) who had sleep disorders, sleep problems, and no sleep disorders/problems. The results showed that PwMS with sleep disorders had significantly lower resilience, with the difference being driven by the support from family and friends. These findings highlight the connection between sleep and resilience in PwMS, emphasizing the importance of social support.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2024)
Article
Clinical Neurology
A. Maunula, S. Atula, Sm Laakso, Pj Tienari
Summary: This study aimed to investigate the frequency and risk factors of FTY rebound in a hospital district in Southern Finland. The results showed that 10.5% of patients experienced a rebound, and 28% of patients had relapses of any severity after discontinuing FTY. Younger age at diagnosis, longer exposure to FTY, lower lymphocyte count, and higher neutrophil to lymphocyte ratio after discontinuation were identified as risk factors for a rebound.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2024)
